A Japanese Pregnant Woman With Treatment‐Resistant Schizophrenia Who Continued Clozapine With Blood Concentration Monitoring During the Perinatal Period and Had a Healthy Baby: A Case Report
Neuropsychopharmacology Reports · 2025-12 · 45 (4)
DOI: 10.1002/npr2.70074 ↗Kurz gefasst
Fallbericht in der Zeitschrift Neuropsychopharmacology Reports, online erschienen am 11.11.2025. Verfasst von Mariko Tsukiji und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacy, Chiba University Hospital, Chiba, Japan. Hauptthemen laut MEDLINE: Clozapine, Antipsychotic Agents, Schizophrenia, Treatment-Resistant, Pregnancy Complications. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Clozapine is known to improve the social functioning of patients with treatment‐resistant schizophrenia (TRS). In Japan, there are few reports on pregnancy and childbirth in patients treated with clozapine, and information on its effects on the fetus and mother is limited. Case Presentation A woman in her 30s with TRS planned her pregnancy while using clozapine (300 mg/day). From around 32 weeks of gestation, she noticed decreased fetal movement and fetal heart rate abnormalities were observed. At 35 weeks of gestation, her clozapine blood concentration was 594 ng/mL (clozapine blood concentration/clozapine dose: C/D ratio, 1.98), which was slightly high, so the dose was reduced to 275 mg/day. With the continuation of clozapine, the mother's psychiatric symptoms remained stable, and she delivered a healthy baby vaginally at 38 weeks of gestation. The clozapine blood concentration increased just before delivery (C/D ratio 2.35) but rapidly decreased after delivery (C/D ratio 1.69). The newborn was discharged in good condition on the fourth day of life.
Conclusion
This case suggests that clozapine can contribute to pregnancy and live birth in TRS patients, but the blood concentration of clozapine may increase more than expected in late pregnancy, necessitating consideration of dose reduction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacy, Chiba University Hospital, Chiba, Japan.
- Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan.
- Division of Child Psychiatry, Chiba University Hospital, Chiba, Japan.
- Department of Obstetrics and Gynecology, Chiba University Hospital, Chiba, Japan.
ORCID-Profile: Mariko Tsukiji
Zitieren
APA
Tsukiji, M., Yamazaki, K., Nakata, Y., Sasaki, T., Idemoto, K., Okada, K., Yamazaki, S., Omoto, A., Koga, K., Niitsu, T., & Ishii, I. (2025). A Japanese Pregnant Woman With Treatment‐Resistant Schizophrenia Who Continued Clozapine With Blood Concentration Monitoring During the Perinatal Period and Had a Healthy Baby: A Case Report. Neuropsychopharmacology Reports, 45(4). https://doi.org/10.1002/npr2.70074
Vancouver
Tsukiji M, Yamazaki K, Nakata Y, Sasaki T, Idemoto K, Okada K, et al. A Japanese Pregnant Woman With Treatment‐Resistant Schizophrenia Who Continued Clozapine With Blood Concentration Monitoring During the Perinatal Period and Had a Healthy Baby: A Case Report. Neuropsychopharmacology Reports. 2025;45(4). doi:10.1002/npr2.70074
BibTeX
@article{Tsukiji2025,
author = {Tsukiji, Mariko and Yamazaki, Kaori and Nakata, Yusuke and Sasaki, Tsuyoshi and Idemoto, Keita and Okada, Kazuki and Yamazaki, Shingo and Omoto, Akiko and Koga, Kaori and Niitsu, Tomihisa and Ishii, Itsuko},
title = {A Japanese Pregnant Woman With Treatment‐Resistant Schizophrenia Who Continued Clozapine With Blood Concentration Monitoring During the Perinatal Period and Had a Healthy Baby: A Case Report},
journal = {Neuropsychopharmacology Reports},
year = {2025},
volume = {45},
number = {4},
doi = {10.1002/npr2.70074}
}
EUVIMED